The present invention relates to new compounds of formula I ##STR00001## wherein Z is N; Y is CONR.sup.5, NR.sup.5CO, SO.sub.2NR.sup.5, NR.sup.5SO.sub.2, CH.sub.2NR.sup.5, NR.sup.5, NR.sup.5CONR.sup.5, CH.sub.2CO, CO, O or CH.sub.2O; X is CH or N; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing one or more atoms selected from C, N, O or S; Q is C.sub.1-6alkyl, C.sub.2-6alkenyl or C.sub.2-6alkynyl, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, such as provide compounds having a selective inhibiting effect at GSK3.